about
Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen.Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma.The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade gliomaSurgical treatment of brain tumors in infants younger than six months of age and review of the literatureStructural brain alterations in children an average of 5 years after surgery and chemotherapy for brain tumors.Pediatric primary intramedullary spinal cord glioblastomaInnovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumorsSuppression of Medulloblastoma Lesions by Forced Migration of Preneoplastic Precursor Cells with Intracerebellar Administration of the Chemokine Cxcl3.The 9L(LUC)/Wistar rat glioma model is not suitable for immunotherapy.The extracellular loops of Smoothened play a regulatory role in control of Hedgehog pathway activation.Efficacy of cabazitaxel in mouse models of pediatric brain tumorsInstitutional experience of paediatric high-grade central nervous system tumours: an analysis of 74 patients and review of the literature.Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas.Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.New approaches to pharmacotherapy of tumors of the nervous system during childhood and adolescence.Treatment of children with high grade glioma with nimotuzumab: a 5-year institutional experienceCentral nervous system injury and neurobiobehavioral function in children with brain tumors: a review of the literature.Quality of life and symptoms in pediatric brain tumor survivors: a systematic review.The genetic signatures of pediatric high-grade glioma: no longer a one-act play.The impact of age and race on longevity in pediatric astrocytic tumors: A population-based study.mTOR pathway as a potential target in a subset of human medulloblastoma.Prognostic significance of cyclin A and B1 in pediatric embryonal tumors.Atypical teratoid rhabdoid tumors of the posterior fossa in children.Pediatric spinal glioblastoma multiforme: current treatment strategies and possible predictors of survival.Survival outcomes in pediatric recurrent high-grade glioma: results of a 20-year systematic review and meta-analysis.Child neurologists should be interested in brain tumors!Thermoresponsive nanocomposite gel for local drug delivery to suppress the growth of glioma by inducing autophagy.Potential role for valproate in the treatment of high--risk brain tumors of childhood-results from a retrospective observational cohort study.A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors.Gene Fusion in Malignant Glioma: An Emerging Target for Next-Generation Personalized Treatment.Reported outcomes of children with newly diagnosed high-grade gliomas treated with nimotuzumab and irinotecan.Prognostic significance of angiogenesis in relation to Ki-67, p-53, p-27, and bcl-2 expression in embryonal tumors.
P2860
Q33392585-DE68108D-8689-4402-A319-21E1459AFD46Q33638876-BAFEDBE3-58E3-4122-A1CE-06C5E8F1DC39Q33751426-11216A42-1293-43CA-9BC4-78EC9BA067ABQ34084319-EC8AD923-FCB0-4575-8310-BE8F882F429CQ34098168-F20AA6E5-1F58-4D76-B665-700D727CF9CFQ34364959-333713F5-C271-4995-861D-C488E606384EQ34480582-26D1CA80-1156-498D-B714-1FABC91ED92BQ34548017-0564EE3E-41CC-48FF-A6DF-BDE54EF644B2Q35020839-2911B2DA-E431-4845-A718-46B964AF3659Q35655642-37F77A18-3501-4675-AE22-7743EA6137EDQ35788771-07A5A1C1-B317-4994-A6FD-DA996BEF56E0Q36942465-3286782C-BACA-48ED-84EC-3B7FAE8CF695Q37238690-F3DD87E9-E282-4107-85EF-236F3DC921EFQ37311185-124B3738-75DE-4CF8-8540-7F3A0F7863DAQ37422646-382BB0DD-4708-4080-AB1A-B39B302E8726Q37484213-229B096D-7816-491B-9F50-E61F7EBCECDCQ38025283-5BC98856-EB2C-4B84-A941-448711675209Q38194432-0DE46DA8-1BCD-45DD-9523-1BE7E37870A8Q38248990-CBF9EE7A-2EAE-47FE-91EF-AEFAC727CA24Q39020317-47F9F284-DD05-4530-B996-E4653BC6BDC6Q39208882-93A723E3-1EA3-442D-A120-1D425D52DF44Q39818480-8F95C28C-A957-4554-8A92-4B11894E765DQ40560695-F7A5B64F-5ECD-4C77-A504-334A94EFA017Q44270548-4EF91CA6-A4D2-40B6-A17F-FF5145AD4D77Q46469386-4FA0A406-2225-44F4-A66E-5B0B081D91D3Q48429676-51EBC982-0F22-4073-99DE-E0488E3E1A2AQ48771370-382B04E1-3807-4592-BAAC-246C40D69B0AQ49135107-9E484AA5-3695-425D-8E98-55EF88585EC8Q52638234-F32C5337-B846-4E28-A5FF-5438951DB7C2Q55457412-97F6D779-6921-41EC-9EF9-60B3AF378FE6Q55458447-E02C1D7A-32A8-4F00-A0E2-13C20CA41EF4Q55462296-AAE3B145-E086-4B9D-BFBF-14074CA762E2
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Chemotherapy for malignant brain tumors of childhood.
@en
Chemotherapy for malignant brain tumors of childhood.
@nl
type
label
Chemotherapy for malignant brain tumors of childhood.
@en
Chemotherapy for malignant brain tumors of childhood.
@nl
prefLabel
Chemotherapy for malignant brain tumors of childhood.
@en
Chemotherapy for malignant brain tumors of childhood.
@nl
P2860
P356
P1476
Chemotherapy for malignant brain tumors of childhood
@en
P2093
Amar Gajjar
P2860
P304
P356
10.1177/0883073808321765
P577
2008-10-01T00:00:00Z